Table 3.

Bivariate Comparison of Primary and Secondary Outcomes Between Patients With Drug Exposures Above Versus Below the Area Under the Curve/Minimum Inhibitory Concentration by Broth Microdilution of 650

Outcome	AUC/MICBMD	Proportion, %	Risk Difference (95% CI)
			Unadjusted	Adjusted
Treatment failure	<650	15.44	0.07 (–.03 to .17)	0.03 (–.06 to .12)
	≥650	22.41
Persistent bacteremia	<650	8.05	0.04 (–.03 to .11)	0.01 (–.07 to .09)
	≥650	12.07
30-d mortality	<650	9.46	0.04 (–.03 to .12)	0.04 (–.02 to .10)
	≥650	14.16
AKIa	<650	21.0	0.12 (.00–.24)	0.09 (–.04 to .22)
	≥650	33.0
VINTa	<650	22.6	0.14 (.01–.26)	0.12 (–.00 to .25)
	≥650	36.4
	AUC/MICEtest	Proportion, %
Treatment failure	<320	11.1	0.10 (.01–.19)	0.07 (–.07 to .22)
	≥320	21.2
Persistent bacteremia	<320	5.56	0.06 (–.01 to .13)	0.07 (–.05 to .19)
	≥320	11.4
30-d mortality	<320	7.04	0.06 (–.02 to .14)	0.07 (–.06 to .20)
	≥320	13.16
AKIa	<320	14.3	0.17 (.05–.28)	0.15 (.02–.29)
	≥320	30.9
VINTa	<320	15.9	0.18 (.06–.29)	0.16 (.02–.30)
	≥320	33.6

Abbreviations: AKI, acute kidney injury; AUC, area under the curve; CI, confidence interval; MIC_BMD, minimum inhibitory concentration by broth microdilution; MIC_Etest, minimum inhibitory concentration by Etest; VINT; vancomycin-induced nephrotoxicity.

^aPatients with baseline serum creatinine (<2.0 mg/dL).